Evidence map›Paper›PMID 33109096›Full record

Observational studyBMC pregnancy and childbirth2020

circCRAMP1L is a novel biomarker of preeclampsia risk and may play a role in preeclampsia pathogenesis via regulation of the MSP/RON axis in trophoblasts.

Yonggang Zhang, Hongling Yang, Yipeng Zhang, Junzhu Shi, Ronggui Chen

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC pregnancy and childbirth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Role of circular RNAs in preeclampsia (Review).Experimental and therapeutic medicine · 2024
    Review
  9. Observational
  10. Current understanding of circular RNAs in preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  11. Review
  12. Review
  13. The pathogenesis of obstetric APS: a 2023 update.Clinical immunology (Orlando, Fla.) · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yonggang ZhangDepartment of Clinical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, 518110, Guangdong, China.
Hongling YangDepartment of Clinical Laboratory, Guangzhou Women and Children's Medical Centre, Guangzhou Medical University, 9, Jinsui Road, Guangzhou, 510623, China. hlyang62@sina.com.
Yipeng ZhangDepartment of Clinical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, 518110, Guangdong, China.
Junzhu ShiDepartment of Clinical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, 518110, Guangdong, China.
Ronggui ChenDepartment of Clinical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, 518110, Guangdong, China.
Guangdong Medical College · CNGuangzhou Medical University · CN

Funding

Science and technology special fund of Longhua District 2017096the National Natural Science Foundation of China 81801474the National Natural Science Foundation of China 81871716The Science and Technology Fund of Guangzhou 201707010019the Science and Technology Fund of Shenzhen JCYJ20180306172502097
6 · The paper itself

Abstract

backgroundPreeclampsia is a severe disease in pregnant women, which is primarily managed by early screening and prevention. Circular RNAs (circRNAs) have increasingly been shown to be important biological regulators involved in numerous diseases. Further, increasing evidence has demonstrated that circRNAs can be used as diagnostic biomarkers. This study was conducted to evaluate the potential of circCRAMP1L, previously identified to be downregulated in preeclampsia, as a novel biomarker for predicting the development of preeclampsia.

methodsWe measured the expression of circCRAMP1L, which is reportedly relevant to trophoblast physiology, in plasma samples from 64 patients with preeclampsia and 64 age-, gestational age-, and body mass index-matched healthy pregnant women by qRT-PCR. MTT proliferation and transwell invasion assays revealed the biological role of circCRAMP1L in preeclampsia pathogenesis. RNA immunoprecipitation and dual-luciferase reporter assays clarified the mechanism underlying the biological function of circCRAMP1L in TEV-1 cells.

resultscircCRAMP1L circulating levels were significantly lower in patients with preeclampsia (2.66 ± 0.82, △Ct value) than in healthy pregnant women (3.95 ± 0.67, △Ct value, p <  0.001). The area under the receiver operating characteristic curve for circCRAMP1L was 0.813. Univariate and multivariate analyses identified circCRAMP1L as an independent predictor of preeclampsia. Furthermore, when circCRAMP1L was utilised in combination with its target protein macrophage stimulating protein (MSP), the predictive performance increased, with an area under the receiver operating characteristic curve of 0.928 (95% CI 0.882-0.974), 80.0% sensitivity, and 80.0% specificity. The in vitro results indicated that circCRAMP1L regulates cell proliferation, and invasion via MSP and RON proteins. We investigated the molecular mechanisms of these effects. In vitro, relative to the control group, circCRAMP1L overexpression significantly enhanced cell proliferation; furthermore, trophoblast cell invasion increased proportionally with circCRAMP1L expression. RNA immunoprecipitation and luciferase reporter gene illustrated that circCRAMP1L participated in regulation of trophoblast cell by regulating MSP.

conclusionReduced plasma levels of circCRAMP1L may be associated with an increased risk of preeclampsia, and circCRAMP1L may be a novel biomarker of preeclampsia risk.

Indexed as

3' Untranslated RegionsAdultBiomarkersCase-Control StudiesCell LineCell MovementCell ProliferationDown-RegulationFemaleHepatocyte Growth FactorHumansPredictive Value of TestsPre-EclampsiaPregnancyProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases3' Untranslated RegionsBiomarkersHepatocyte Growth Factormacrophage stimulating proteinProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRNA, CircularRON proteincircCRAMP1LMSP/RONPreeclampsia

Identifiers

PMID33109096
PMCPMC7590488
OpenAlexW3096158687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.